Paul Carter Net Worth

The estimated Net Worth of Paul Rutherford Carter is at least $422 mil dollars as of 1 August 2016. Mr. Carter owns over 2,000 units of Mallinckrodt Plc stock worth over $21,864 and over the last 11 years he sold MNK stock worth over $0. In addition, he makes $400,000 as Independent Director at Mallinckrodt Plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Carter MNK stock SEC Form 4 insiders trading

Paul has made over 44 trades of the Mallinckrodt Plc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 2,000 units of MNK stock worth $78,260 on 1 August 2016.

The largest trade he's ever made was exercising 99,000 units of Mallinckrodt Plc stock on 14 February 2014 worth over $2,376,000. On average, Paul trades about 6,500 units every 16 days since 2014. As of 1 August 2016 he still owns at least 64,305 units of Mallinckrodt Plc stock.

You can see the complete history of Mr. Carter stock trades at the bottom of the page.

Paul Carter biography

Paul Rutherford Carter has been appointed as Independent Director of the Company. Mr. Carter served in various roles at Gilead Sciences, Inc., a research based biopharmaceutical company, from April 2006 to August 2016, most recently serving as Executive Vice President, Commercial Operations. Prior to joining Gilead, Mr. Carter spent 15 years in the pharmaceutical industry with GlaxoSmithKline and its legacy companies where he held various roles with increasing levels of senior experience, including General Manager in Europe and as a Regional Head of the International Business in Asia. Mr. Carter also serves as a healthcare advisor to several biotechnology companies. Mr. Carter has served as a director of Alder Biopharmaceuticals, Inc. since 2015 and Hutchison China MediTech Ltd. since 2017. Mr. Carter’s qualifications to serve on our Board include extensive experience with multinational companies in the pharmaceutical industry, including involvement with the launch and commercialization of various medicines worldwide, as well as his experience as a director of publicly traded pharmaceutical companies.

What is the salary of Paul Carter?

As the Independent Director of Mallinckrodt Plc, the total compensation of Paul Carter at Mallinckrodt Plc is $400,000. There are 11 executives at Mallinckrodt Plc getting paid more, with Mark Trudeau having the highest compensation of $14,610,800.

How old is Paul Carter?

Paul Carter is 59, he's been the Independent Director of Mallinckrodt Plc since 2018. There are 7 older and 6 younger executives at Mallinckrodt Plc. The oldest executive at Mallinckrodt Plc is J. Martin Carroll, 70, who is the Independent Director.

What's Paul Carter's mailing address?

Paul's mailing address filed with the SEC is McDonnell Boulevard, Hazelwood, Saint Louis County, Missouri, 63042, United States.

Insiders trading at Mallinckrodt Plc

Over the last 11 years, insiders at Mallinckrodt Plc have traded over $29,853,069 worth of Mallinckrodt Plc stock and bought 2,559,592 units worth $174,429,961 . The most active insiders traders include & Co. Inc. Paulson, James E Deerfield Mgmt L.P.... y Nancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of $10,061. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth $9,495.

What does Mallinckrodt Plc do?

mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit

Complete history of Mr. Carter stock trades at Gilead Sciences y Mallinckrodt Plc

Mallinckrodt Plc executives and stock owners

Mallinckrodt Plc executives and other stock owners filed with the SEC include:

• Mark Trudeau,
  President, Chief Executive Officer, Director
• Steven Romano,
  Executive Vice President, Chief Scientific Officer
• Hugh O'Neill,
  Executive Vice President, Chief Commercial Officer
• Mark Casey,
  Executive Vice President and Chief Legal Officer
• Bryan Reasons,
  Chief Financial Officer, Executive Vice President
• Ian Watkins,
  Chief Human Resource Officer, Executive Vice President
• Angus Russell,
  Independent Non-Executive Chairman of the Board
• JoAnn Reed,
  Independent Director
• J. Martin Carroll,
  Independent Director
• David Norton,
  Independent Director
• Kneeland Youngblood,
  Independent Director
• Anne Whitaker,
  Independent Director
• Paul Carter,
  Independent Director
• Carlos Paya,
  Independent Director
• Daniel Speciale,
  Vice President - Investor Relations and IRO
• David R Carlucci,
  Director
• Virgil D Thompson,
  Director
• Diane H. Gulyas,
  Director
• Matthew K Harbaugh,
  SVP&Chief Financial Officer
• Michael Bryant Hicks,
  Sr. VP & General Counsel
• Ronald K. Lloyd,
  Sr. VP & Pres, Hospital
• Raymond J. Furey,
  SVP & Chief Compliance Officer
• Gary M. Phillips,
  Sr. VP & Chief Strategy Ofcr.
• Meredith B Fischer,
  SVP, Communic. & Public Affair
• Melvin D Booth,
  Director
• Joseph A Zaccagnino,
  Director
• Coleman N Iii Lannum,
  VP, Investor Relations
• Dagmar Rosa Bjorkeson,
  Chief Strat & Corp Dev Officer
• Sigurdur O Olafsson,
  President and CEO
• Kassie Harrold,
  Chief Compliance Officer
• Jason Daniel Goodson,
  EVP & Head of Corp Development
• Henriette Nielsen,
  EVP & Chief Transformation OFC
• Lisa French,
  EVP & Chief Commercial Officer
• Mark Anthony Tyndall,
  EVP & Chief Legal Offi & Secre
• Stephen Andrew Welch,
  EVP & Head of Spec Generics
• Frank Scholz,
  SVP, Global Operations
• George A. Kegler,
  EVP & CFO, Interim
• Karen Patruno Sheehy,
  Sr. VP & Chief Compliance Off.
• James E Deerfield Mgmt L.P....,
  
• Don M Bailey,
  Director
• Sandra L Hatten,
  Sr. Vice President Quality
• Terrance L Carlson,
  Interim General Counsel
• & Co. Inc. Paulson,
  10% owner
• Holding Ltd Enceladus,
  
• Thomas E Berry,
  See Remarks
• Peter G Edwards,
  See Remarks
• Stefano R Carchedi,
  See Remarks
• Stephen Merrick,
  See Remarks
• Nancy Lurker,
  Director
• Mario D. Saltarelli,
  Sr. VP & Chief Science Ofcr.
• Kathy A Schaefer,
  Sr. VP Fin & Corp. Controller
• Peter C Richardson,
  EVP & Chief Scientific Officer
• Daniel Arthur Celentano,
  Director
• Woodrow A Jr Myers,
  Director
• Paul Bisaro,
  Director
• James R Sulat,
  Director
• Susan Michele Silbermann,
  Director
• Karen Ling,
  Director
• Neal P Goldman,
  Director
• Riad Hussein El Dada,
  Director